Search PubMed⌕ Search

Biomedical subjects

A Martini

Publications and source records attributed to A Martini.

At least 289 records · Page 16Linked to original sources
PubMed1985

Immunological evaluation in children with juvenile chronic arthritis treated with auranofin.

An immunological evaluation was performed before therapy and every four months during the first year of treatment with auranofin in 6 children with juvenile chronic arthritis. The immunological tests included: IgG, IgA, IgM, IgE and "natural" antibody serum levels, CH50 of the classical and alternative complement pathways, PWM-induced IgM production in vitro, and polymorphonuclear neutrophil functions. A reduction of the in vitro IgM synthesis and in the CH50 of the classical pathway of complement, and a normalization of impaired chemotaxis, occurred in patients who presented a clinically significant improvement during auranofin treatment.

Antibody Formation↗
PubMed1985

[Concentration of various bioelements in the serum of otosclerosis patients].

Serum biochemistry was monitored in 50 patients with otosclerosis confirmed surgically. Age distribution was 25 to 50 years (mean:30 years), and the group included 8 men. Constants determined were serum sodium, potassium, chlorine, iron, phosphorus, aluminium, magnesium, copper and alkaline phosphatase. All patients were free from systemic or metabolic disease. Results failed to demonstrate variations in sodium, potassium, iron, and chlorine concentrations when compared with controls, with non-significant differences in copper, magnesium, phosphorus, aluminium and alkaline phosphatases. These findings were observed both in young patients in whom the otosclerotic process is in the active phase, and in older patients, this excluding correlations between duration of the disease and variations in concentrations of specific ions. The presence of aluminium in the active otosclerotic process is therefore due to local factors of which the mechanism is unknown at the present time.

Adult↗
PubMed1985

[Transient stenosing ureteritis in childhood. A rare complication of rheumatoid purpura].

A case of transient stenosing ureteritis in a boy presenting with the clinical features of Henoch-Schoenlein purpura (diffuse articular swelling, petechiae, abdominal pain) complicated by macroscopic haematuria with blood clots is reported. On urography the right collecting system and the right ureter up to the distal lumbar portion were dilated owing to tight ureteral stenosis at that level. Above the stricture, numerous ring-like functional ureteral wall defects were detectable. On the left a stenosis was evident at the lumbo-sacral level with mild dilatation of the ureter. A small filling defect due to subephitelial haemorrhage was evident in the upper part of this ureter. Three months later, after prednisone therapy, the urography was normal on the right: residual mild stenosis was still evident on the left. Radiological findings in Henoch-Schoenlein purpura and the possible differential diagnosis of this condition are discussed.

Child, Preschool↗
PubMed1984

Kappa-receptor antagonist reverse 'non-opioid' stress-induced analgesia.

We have evaluated the effects of antagonists to the mu, kappa and opiate receptors on 'opioid' and 'non-opioid mediated' analgesia. Our findings indicate that mu receptors might mediate 'opioid' and kappa receptors 'non-opioid' analgesia. It is suggested that endogenous opiates that act on mu or kappa receptors could be responsible for the different types of stress-induced analgesia.

Animals↗
PubMed1984

Effects of beta-endorphin fragment 6-31 on morphine- and beta-endorphin-induced growth hormone and prolactin release.

A fragment of human beta-endorphin (beta h-EP-(6-31] has been proposed as an endogenous inhibitor of beta-endorphin. We have evaluated the effects of the fragment on beta-endorphin- and morphine-induced prolactin and growth hormone release. It inhibited both morphine- and beta-endorphin-induced prolactin release, while it was ineffective on the release of growth hormone.

Animals↗
PubMed1984

Hepatitis B virus infection and Schönlein-Henoch purpura.

Sch onlein -Henoch purpura developed in two children in association with hepatitis B virus (HBV) infection. The first child, an 8-year-old boy, first had a clinical picture of Sch onlein -Henoch purpura and then was found to have HBV-related chronic persistent hepatitis. In the second child, a 6-year-old girl, characteristic skin lesions, arthralgia, and proteinuria developed during acute hepatitis B. Immunofluorescence demonstrated IgA deposition in the renal glomeruli of the first patient. We suggest that evidence of HBV infection should be sought in patients with Sch onlein -Henoch purpura.

Acute Disease↗
PubMed1984

A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.

Sixty-six patients with advanced solid tumors were treated with 4'-epi-doxorubicin at a dose of 90 mg/m2 by rapid IV injection every 21 days until the disease had progressed or to a maximum cumulative dose of 540 mg/m2. Myelosuppression, nausea and vomiting, and alopecia were the almost frequent side effects, but their incidence seemed lower than that after a comparable dosage of doxorubicin. After a cumulative dose of 540 mg/m2 a significant decrease of QRS complex deflection on the electrocardiogram was detected, but no case of congestive heart failure was observed. Partial remission and minor remission were achieved, respectively, in nine (15%) and five (9%) out of 59 evaluable patients for a median duration of 6 months. Partial remission occurred in anthracycline-sensitive tumors like breast cancer (4 of 13), lung cancer (1 of 17), head and neck cancer (1 of 8), gastric cancer (2 of 4), and ovarian cancer (1 of 1).

Adult↗
PubMed1984

Ozena as presenting symptom of a rare and severe genetic disease: hypohidrotic ectodermal dysplasia.

Ozena is quite a common clinical finding in ENT practice in many countries, but even if the pathological picture is clear, its etiology is unknown. We report on two young females in which ozena was the presenting symptom of a rare and severe genetic disorder (hypohidrotic ectodermal dysplasia, HED). Etiopathogenetic theories on ozena and genetic problems of HED are discussed.

Adolescent↗
PubMed1984

Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission.

The kinetics at steady state of prednisone and its metabolite prednisolone were determined in nine nephrotic children during the active phase of the disease and in remission. There were no differences in serum prednisone levels between the two occasions. Prednisone levels were lower than prednisolone levels. Total serum prednisolone levels were significantly lower during the active phase than in remission (AUC: 2452 +/- 207 vs 3392 +/- 293 ng ml-1 h respectively). Half-life values were similar on both occasions. The binding of prednisolone to serum proteins was markedly impaired during the active phase as compared to the remission. Free fraction values correlated positively with total drug concentration. A negative correlation between free fraction and serum albumin level was found during the active phase. Free prednisolone levels during the active phase did not differ significantly from those observed during remission (AUC: 937 +/- 128 vs 847 +/- 81 ng ml-1 h respectively). These data indicate that pharmacokinetic changes are unlikely to be responsible for alterations in steroid responsiveness in nephrotic patients with hypoalbuminaemia.

Adolescent↗
PubMed1984

Antiepileptic agents affect hypothalamic beta-endorphin concentrations.

beta-Endorphin, Met-enkephalin, substance P, and somatostatin concentrations were evaluated in the hypothalami of rats treated either acutely or chronically (15 days) with sodium valproate, diphenylhydantoin, phenobarbital, or ethosuximide. All of these drugs, with the exception of ethosuximide, induced significant decreases in beta-endorphin concentrations after acute treatment, while only sodium valproate induced a decrease after chronic treatment. The acute and chronic effects of sodium valproate were also produced by aminooxyacetic acid, an inhibitor of gamma-aminobutyric acid (GABA) transaminase, while another GABA transaminase inhibitor, ethanolamine-O-sulphate, and THIP, a GABA receptor agonist, were effective after acute administration. Metenkephalin, substance P, and somatostatin concentrations were never affected by the drugs used. The present results, indicating that antiepileptic agents specifically decrease beta-endorphin concentrations, seem to correlate well with the capacity of these agents to blunt the epileptic activity of the peptides tested. Moreover, our data suggest that GABA may be involved in the anticonvulsant-induced reduction of beta-endorphin concentrations.

Animals↗